Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 29, 2019
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinomaE L Mayer, A DeMichele, H S Rugo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancerH J Burstein, I Kuter, S M Campos, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Third consensus on medical treatment of metastatic breast cancerS Beslija, J Bonneterre, H J Burstein, et al.ESMO Open|July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancerR Jeselsohn, J Fu, Y Ren, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.Pageof 5